Cargando…

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

BACKGROUND: The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan. METHODS: Phosphokinome profiling with peptide arrays of tumour samples from nude mice xenografted with HT29 cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tosi, Diego, Pérez-Gracia, Esther, Atis, Salima, Vié, Nadia, Combès, Eve, Gabanou, Mélissa, Larbouret, Christel, Jarlier, Marta, Mollevi, Caroline, Torro, Adeline, Del Rio, Maguy, Martineau, Pierre, Gongora, Céline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090616/ https://www.ncbi.nlm.nih.gov/pubmed/30103709 http://dx.doi.org/10.1186/s12885-018-4712-z

Ejemplares similares

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
por: Marzi, L, et al.
Publicado: (2016)

Specific Extracellular Matrix Remodeling Signature of Colon Hepatic Metastases
por: Del Rio, Maguy, et al.
Publicado: (2013)

Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells
por: Denis, Vincent, et al.
Publicado: (2022)

Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells
por: Vié, Nadia, et al.
Publicado: (2008)

Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry
por: Vezzio-Vié, Nadia, et al.
Publicado: (2022)

Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype
por: Cherradi, Sara, et al.
Publicado: (2019)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
por: Rabia, Emilia, et al.
Publicado: (2021)

New Topoisomerase I mutations are associated with resistance to camptothecin
por: Gongora, Céline, et al.
Publicado: (2011)

Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells
por: Cherradi, Sara, et al.
Publicado: (2023)

Antibody targeting of claudin-1 as a potential colorectal cancer therapy
por: Cherradi, S., et al.
Publicado: (2017)

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
por: Viala, Marie, et al.
Publicado: (2018)

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
por: Thierry, Alain R., et al.
Publicado: (2010)

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
por: Thomas, GaëLle, et al.
Publicado: (2014)

High Fragmentation Characterizes Tumour-Derived Circulating DNA
por: Mouliere, Florent, et al.
Publicado: (2011)

FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
por: Westover, David, et al.
Publicado: (2015)

Letrozole sensitizes breast cancer cells to ionizing radiation
por: Azria, David, et al.
Publicado: (2005)

Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures
por: Larbouret, Christel, et al.
Publicado: (2021)

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2012)

Intergroup Conflict and Rational Decision Making
por: Martínez-Tur, Vicente, et al.
Publicado: (2014)

Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells
por: Corvaglia, Valentina, et al.
Publicado: (2021)

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
por: Assenat, Eric, et al.
Publicado: (2015)

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
por: Leenhardt, Fanny, et al.
Publicado: (2022)

Exploring condom use decision-making among adolescents: the synergistic role of affective and rational processes
por: Davids, Eugene L., et al.
Publicado: (2021)

Rational design of iridium–porphyrin conjugates for novel synergistic photodynamic and photothermal therapy anticancer agents
por: Zhang, Liping, et al.
Publicado: (2021)

Self-assembly of nanomicelles with rationally designed multifunctional building blocks for synergistic chemo-photodynamic therapy
por: Gong, Guidong, et al.
Publicado: (2022)

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer
por: Azria, D, et al.
Publicado: (2003)

Optimal biological dose: a systematic review in cancer phase I clinical trials
por: Fraisse, J., et al.
Publicado: (2021)

High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance
por: Wambaugh, Morgan A., et al.
Publicado: (2017)

EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA
por: Bakhshinyan, David, et al.
Publicado: (2021)

Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death
por: Guest, Stephen T., et al.
Publicado: (2016)

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
por: Liu, Zuqiang, et al.
Publicado: (2017)

Rational design of non-toxic GOx-based biocatalytic nanoreactor for multimodal synergistic therapy and tumor metastasis suppression
por: Hang, Lifeng, et al.
Publicado: (2021)

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
por: Rabia, Emilia, et al.
Publicado: (2023)

Embodying Bounded Rationality: From Embodied Bounded Rationality to Embodied Rationality
por: Petracca, Enrico
Publicado: (2021)

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation
por: Le Clorennec, Christophe, et al.
Publicado: (2016)

Rational or rationalized choices in fluid resuscitation?
por: Han, Jenny, et al.
Publicado: (2010)

Phenylbutyrate Is Bacteriostatic against Mycobacterium tuberculosis and Regulates the Macrophage Response to Infection, Synergistically with 25-Hydroxy-Vitamin D₃
por: Coussens, Anna K., et al.
Publicado: (2015)

Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia
por: Ding, Yang-Yang, et al.
Publicado: (2021)

Rational Design of Synergistic Structure Between Single-Atoms and Nanoparticles for CO(2) Hydrogenation to Formate Under Ambient Conditions
por: Zhai, Shengliang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qm774joimvk0op1a53q2shh4q9